ASPsiRNA: A resource of ASP-siRNAs having therapeutic potential for human genetic disorders and algorithm for prediction of their inhibitory efficacy

G3: Genes, Genomes, Genetics

Volumn 7, Issue 9, 2017, Pages 2931-2943

  Monga, Isha ^a   Qureshi, Abid ^a   Thakur, Nishant ^a   Gupta, Amit Kumar ^a   Kumar, Manoj ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

Algorithm; Allele specific; ASPsiDb; ASPsiPred; Database; Genetic disease; Prediction; SiRNA

Indexed keywords

ALLELE SPECIFIC SMALL INTERFERING RNA; ATELOCOLLAGEN; LENTIVIRUS VECTOR; MESSENGER RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACCURACY; ALGORITHM; ARTICLE; AUTOIMMUNE DISEASE; BONE DISEASE; ELECTROPORATION; EXPRESSION VECTOR; FLUORESCENCE MICROSCOPY; GENE MUTATION; GENETIC DISORDER; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; INDEL MUTATION; LUCIFERASE ASSAY; MALIGNANT NEOPLASM; MISSENSE MUTATION; MUSCLE DISEASE; NEUROLOGIC DISEASE; NONHUMAN; PREDICTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; SUPPORT VECTOR MACHINE; WESTERN BLOTTING; ALLELE; BIOLOGY; GENETIC DATABASE; GENETICS; MUTATION; PROCEDURES; REPRODUCIBILITY; RNA INTERFERENCE; RNAI THERAPEUTICS; SOFTWARE; WEB BROWSER; WORKFLOW;

ALGORITHMS; ALLELES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENETIC DISEASES, INBORN; HUMANS; MUTATION; REPRODUCIBILITY OF RESULTS; RNA INTERFERENCE; RNA, SMALL INTERFERING; RNAI THERAPEUTICS; SOFTWARE; WEB BROWSER; WORKFLOW;

EID: 85029109747     PISSN: None     EISSN: 21601836     Source Type: Journal    
DOI: 10.1534/g3.117.044024     Document Type: Article

References (89)

1. Aharony, I., D. E. Ehrnhoefer, A. Shruster, X. Qiu, S. Franciosi et al., 2015 A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum. Mol. Genet. 24: 2604-2614.
2. Ahmed, F., and G. P. Raghava, 2011 Designing of highly effective complementary and mismatch siRNAs for silencing a gene. PLoS One 6: e23443.
3. Allen, E. H., S. D. Atkinson, H. Liao, J. E. Moore, D. M. Leslie Pedrioli et al., 2013 Allele-specific siRNA silencing for the common keratin 12 founder mutation in Meesmann epithelial corneal dystrophy. Invest. Ophthalmol. Vis. Sci. 54: 494-502.
4. Alves, S., I. Nascimento-Ferreira, G. Auregan, R. Hassig, N. Dufour et al., 2008 Allele-specific RNA silencing of mutant ataxin-3 mediates neuroprotection in a rat model of Machado-Joseph disease. PLoS One 3: e3341.
5. Amarzguioui, M., and H. Prydz, 2004 An algorithm for selection of functional siRNA sequences. Biochem. Biophys. Res. Commun. 316: 1050-1058.
6. Arribat, Y., N. Bonneaud, Y. Talmat-Amar, S. Layalle, M. L. Parmentier et al., 2013 A huntingtin peptide inhibits polyQ-huntingtin associated defects. PLoS One 8: e68775.
7. Atkinson, S. D., V. E. McGilligan, H. Liao, I. Szeverenyi, F. J. Smith et al., 2011 Development of allele-specific therapeutic siRNA for keratin 5 mutations in epidermolysis bullosa simplex. J. Invest. Dermatol. 131: 2079-2086.
8. Birmingham, A., E. M. Anderson, A. Reynolds, D. Ilsley-Tyree, D. Leake et al., 2006 39 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 3: 199-204.
9. Caplen, N. J., J. P. Taylor, V. S. Statham, F. Tanaka, A. Fire et al., 2002 Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference. Hum. Mol. Genet. 11: 175-184.
10. Courtney, D. G., S. D. Atkinson, J. E. Moore, E. Maurizi, C. Serafini et al., 2014 Development of allele-specific gene-silencing siRNAs for TGFBI Arg124Cys in lattice corneal dystrophy type I. Invest. Ophthalmol. Vis. Sci. 55: 977-985.
11. Dar, S. A., A. K. Gupta, A. Thakur, and M. Kumar, 2016a SMEpred workbench: a web server for predicting efficacy of chemically modified siRNAs. RNA Biol. 13: 1144-1151.
12. Dar, S. A., A. Thakur, A. Qureshi, and M. Kumar, 2016b siRNAmod: a database of experimentally validated chemically modified siRNAs. Sci. Rep. 6: 20031.
13. Davidson, B. L., and H. L. Paulson, 2004 Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol. 3: 145-149.
14. Drouet, V., M. Ruiz, D. Zala, M. Feyeux, G. Auregan et al., 2014 Allelespecific silencing of mutant huntingtin in rodent brain and human stem cells. PLoS One 9: e99341.
15. Elbashir, S. M., J. Harborth, W. Lendeckel, A. Yalcin, K. Weber et al., 2001a Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498.
16. Elbashir, S. M., J. Martinez, A. Patkaniowska, W. Lendeckel, and T. Tuschl, 2001b Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 20: 6877-6888.
17. Filhol, O., D. Ciais, C. Lajaunie, P. Charbonnier, N. Foveau et al., 2012 DSIR: assessing the design of highly potent siRNA by testing a set of cancer-relevant target genes. PLoS One 7: e48057.
18. Fire, A., S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver et al., 1998 Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811.
19. Gonzalez-Alegre, P., 2007 Therapeutic RNA interference for neurodegenerative diseases: from promise to progress. Pharmacol. Ther. 114: 34-55.
20. Gonzalez-Alegre, P., V. M. Miller, B. L. Davidson, and H. L. Paulson, 2003 Toward therapy for DYT1 dystonia: allele-specific silencing of mutant TorsinA. Ann. Neurol. 53: 781-787.
21. Gonzalez-Alegre, P., N. Bode, B. L. Davidson, and H. L. Paulson, 2005 Silencing primary dystonia: lentiviral-mediated RNA interference therapy for DYT1 dystonia. J. Neurosci. 25: 10502-10509.
22. Haley, B., and P. D. Zamore, 2004 Kinetic analysis of the RNAi enzyme complex. Nat. Struct. Mol. Biol. 11: 599-606.
23. Hamosh, A., A. F. Scott, J. Amberger, D. Valle, and V. A. McKusick, 2000 Online mendelian inheritance in man (OMIM). Hum. Mutat. 15: 57-61.
24. Holen, T., 2006 Efficient prediction of siRNAs with siRNArules 1.0: an open-source JAVA approach to siRNA algorithms. RNA 12: 1620-1625.
25. Huang, H., R. Qiao, D. Zhao, T. Zhang, Y. Li et al., 2009 Profiling of mismatch discrimination in RNAi enabled rational design of allelespecific siRNAs. Nucleic Acids Res. 37: 7560-7569.
26. Huesken, D., J. Lange, C. Mickanin, J. Weiler, F. Asselbergs et al., 2005 Design of a genome-wide siRNA library using an artificial neural network. Nat. Biotechnol. 23: 995-1001.
27. Ichihara, M., Y. Murakumo, A. Masuda, T. Matsuura, N. Asai et al., 2007 Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities. Nucleic Acids Res. 35: e123.
28. Iyer, S. V., A. Parrales, P. Begani, A. Narkar, A. S. Adhikari et al., 2016 Allele-specific silencing of mutant p53 attenuates dominantnegative and gain-of-function activities. Oncotarget 7: 5401-5415.
29. Jackson, A. L., S. R. Bartz, J. Schelter, S. V. Kobayashi, J. Burchard et al., 2003 Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21: 635-637.
30. Jamwal, S., and P. Kumar, 2015 Antidepressants for neuroprotection in Huntington's disease: a review. Eur. J. Pharmacol. 769: 33-42.
31. Jiang, P., H. Wu, Y. Da, F. Sang, J. Wei, et al. 2007 RFRCDB-siRNA: improved design of siRNAs by random forest regression model coupled with database searching. Comput Methods Programs Biomed 87: 230-238.
32. Jiang, J., H. Wakimoto, J. G. Seidman, and C. E. Seidman, 2013 Allelespecific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science 342: 111-114.
33. Kamola, P. J., Y. Nakano, T. Takahashi, P. A. Wilson, and K. Ui-Tei, 2015 The siRNA non-seed region and its target sequences are auxiliary determinants of off-target effects. PLoS Comput. Biol. 11: e1004656.
34. Kaur, K., A. K. Gupta, A. Rajput, and M. Kumar, 2016 ge-CRISPR-an integrated pipeline for the prediction and analysis of sgRNAs genome editing efficiency for CRISPR/Cas system. Sci. Rep. 6: 30870.
35. Keiser, M. S., J. H. Kordower, P. Gonzalez-Alegre, and B. L. Davidson, 2015 Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy. Brain 138: 3555-3566.
36. Keiser, M. S., H. B. Kordasiewicz, and J. L. McBride, 2016 Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia. Hum. Mol. Genet. 25: R53-R64.
37. Krzywinski, M., J. Schein, I. Birol, J. Connors, R. Gascoyne et al., 2009 Circos: an information aesthetic for comparative genomics. Genome Res. 19: 1639-1645.
38. Kulshreshtha, A., and P. Piplani, 2016 Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease. Neurol. Sci. 37: 1403-1435.
39. Kumar, M., S. Lata, and G. Raghava, 2009 siRNApred: SVM based method for predicting efficacy value of siRNA. Paper presented at: Proceedings of the first international conference on Open Source for Computer Aided Drug Discovery (OSCADD) (CSIR-IMTECH).
40. Lander, E. S., 2011 Initial impact of the sequencing of the human genome. Nature 470: 187-197.
41. Landrum, M. J., J. M. Lee, G. R. Riley, W. Jang, W. S. Rubinstein et al., 2014 ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 42: D980-D985.
42. Lappalainen, I., J. Lopez, L. Skipper, T. Hefferon, J. D. Spalding et al., 2013 DbVar and DGVa: public archives for genomic structural variation. Nucleic Acids Res. 41: D936-D941.
43. Leachman, S. A., R. P. Hickerson, P. R. Hull, F. J. Smith, L. M. Milstone et al., 2008 Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J. Dermatol. Sci. 51: 151-157.
44. Leachman, S. A., R. P. Hickerson, M. E. Schwartz, E. E. Bullough, S. L. Hutcherson et al., 2010 First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 18: 442-446.
45. LeWitt, P. A., R. A. Hauser, D. G. Grosset, F. Stocchi, M. H. Saint-Hilaire et al., 2016 A randomized trial of inhaled levodopa (CVT-301) for motor fluctuations in Parkinson's disease. Mov. Disord. 31: 1356-1365.
46. Liu, Y., E. R. Snedecor, X. Zhang, Y. Xu, L. Huang et al., 2016 Correction of hair shaft defects through allele-specific silencing of mutant Krt75. J. Invest. Dermatol. 136: 45-51.
47. Lombardi, M. S., L. Jaspers, C. Spronkmans, C. Gellera, F. Taroni et al., 2009 A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol. 217: 312-319.
48. Lopes, C., S. Aubert, F. Bourgois-Rocha, M. Barnat, A. C. Rego et al., 2016 Dominant-negative effects of adult-onset huntingtin mutations alter the division of human embryonic stem cells-derived neural cells. PLoS One 11: e0148680.
49. Loy, R. E., J. D. Lueck, M. A. Mostajo-Radji, E. M. Carrell, and R. T. Dirksen, 2012 Allele-specific gene silencing in two mouse models of autosomal dominant skeletal myopathy. PLoS One 7: e49757.
50. Lussier, Y. A., H. Li, and M. Maienschein-Cline, 2013 Conquering computational challenges of omics data and post-ENCODE paradigms. Genome Biol. 14: 310.
51. Lyu, Y. S., P. L. Shi, X. L. Chen, Y. X. Tang, Y. F. Wang et al., 2016 A small indel mutant mouse model of epidermolytic palmoplantar keratoderma and its application to mutant-specific shRNA therapy. Mol. Ther. Nucleic Acids 5: e299.
52. Marelli, C., and F. Maschat, 2016 The P42 peptide and peptide-based therapies for Huntington's disease. Orphanet J. Rare Dis. 11: 24.
53. Mazur, S., G. Csucs, and K. Kozak, 2012 RNAiAtlas: a database for RNAi (siRNA) libraries and their specificity. Database (Oxford) 2012: bas027.
54. McQuisten, K. A., and A. S. Peek, 2009 Comparing artificial neural networks, general linear models and support vector machines in building predictive models for small interfering RNAs. PLoS One 4: e7522.
55. Miller, V. M., H. Xia, G. L. Marrs, C. M. Gouvion, G. Lee et al., 2003 Allelespecific silencing of dominant disease genes. Proc. Natl. Acad. Sci. USA 100: 7195-7200.
56. Miller, V. M., C. M. Gouvion, B. L. Davidson, and H. L. Paulson, 2004 Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res. 32: 661-668.
57. Miniarikova, J., I. Zanella, A. Huseinovic, T. van der Zon, E. Hanemaaijer et al., 2016 Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington's disease. Mol. Ther. Nucleic Acids 5: e297.
58. Mook, O. R., F. Baas, M. B. de Wissel, and K. Fluiter, 2009 Allele-specific cancer cell killing in vitro and in vivo targeting a single-nucleotide polymorphism in POLR2A. Cancer Gene Ther. 16: 532-538.
59. Mysara, M., J. M. Garibaldi, and M. Elhefnawi, 2011 MysiRNA-designer: a workflow for efficient siRNA design. PLoS One 6: e25642.
60. Nabzdyk, C. S., M. Chun, L. Pradhan, and F. W. Logerfo, 2011 High throughput RNAi assay optimization using adherent cell cytometry. J. Transl. Med. 9: 48.
61. Ohnishi, Y., Y. Tamura, M. Yoshida, K. Tokunaga, and H. Hohjoh, 2008 Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. PLoS One 3: e2248.
62. Pan, W. J., C. W. Chen, and Y. W. Chu, 2011 siPRED: predicting siRNA efficacy using various characteristic methods. PLoS One 6: e27602.
63. Pandey, S. K., T. M. Wheeler, S. L. Justice, A. Kim, H. S. Younis et al., 2015 Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J. Pharmacol. Exp. Ther. 355: 329-340.
64. Paulson, H., and P. Gonzalez-Alegre, 2006 RNAi gets its prize. Lancet Neurol. 5: 997-999.
65. Peek, A. S., 2007 Improving model predictions for RNA interference activities that use support vector machine regression by combining and filtering features. BMC Bioinformatics 8: 182.
66. Qureshi, A., N. Thakur, and M. Kumar, 2013 VIRsiRNApred: a web server for predicting inhibition efficacy of siRNAs targeting human viruses. J. Transl. Med. 11: 305.
67. Qureshi, A., N. Thakur, I. Monga, A. Thakur, and M. Kumar, 2014 VIRmiRNA: a comprehensive resource for experimentally validated viral miRNAs and their targets. Database (Oxford) 2014: bau103.
68. Ren, Y., W. Gong, Q. Xu, X. Zheng, D. Lin et al., 2006 siRecords: an extensive database of mammalian siRNAs with efficacy ratings. Bioinformatics 22: 1027-1028.
69. Reynolds, A., D. Leake, Q. Boese, S. Scaringe, W. S. Marshall et al., 2004 Rational siRNA design for RNA interference. Nat. Biotechnol. 22: 326-330.
70. Rodriguez-Lebron, E., and H. L. Paulson, 2006 Allele-specific RNA interference for neurological disease. Gene Ther. 13: 576-581.
71. Saetrom, P., 2004 Predicting the efficacy of short oligonucleotides in antisense and RNAi experiments with boosted genetic programming. Bioinformatics 20: 3055-3063.
72. Schwarz, D. S., H. Ding, L. Kennington, J. T. Moore, J. Schelter et al., 2006 Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet. 2: e140.
73. Seyhan, A. A., 2011 RNAi: a potential new class of therapeutic for human genetic disease. Hum. Genet. 130: 583-605.
74. Shabalina, S. A., A. N. Spiridonov, and A. Y. Ogurtsov, 2006 Computational models with thermodynamic and composition features improve siRNA design. BMC Bioinformatics 7: 65.
75. Sherry, S. T., M. Ward, and K. Sirotkin, 1999 dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res. 9: 677-679.
76. Sierant, M., A. Paduszynska, J. Kazmierczak-Baranska, B. Nacmias, S. Sorbi et al., 2011 Specific silencing of L392V PSEN1 mutant allele by RNA interference. Int. J. Alzheimers Dis. 2011: 809218.
77. Squitieri, F., and J. G. de Yebenes, 2015 Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date. Drug Des. Devel. Ther. 9: 5827-5833.
78. Takahashi, M., M. Suzuki, M. Fukuoka, N. Fujikake, S. Watanabe et al., 2015 Normalization of overexpressed alpha-synuclein causing Parkinson's disease by a moderate gene silencing with RNA interference. Mol. Ther. Nucleic Acids 4: e241.
79. Teng, X., J. Y. Liu, D. Li, Y. Fang, X. Y. Wang et al., 2011 Application of allele-specific RNAi in hepatitis B virus lamivudine resistance. J. Viral Hepat. 18: e491-e498.
80. Thakur, N., A. Qureshi, and M. Kumar, 2012a AVPpred: collection and prediction of highly effective antiviral peptides. Nucleic Acids Res. 40: W199-W204.
81. Thakur, N., A. Qureshi, and M. Kumar, 2012b VIRsiRNAdb: a curated database of experimentally validated viral siRNA/shRNA. Nucleic Acids Res. 40: D230-D236.
82. Trochet, D., B. Prudhon, S. Vassilopoulos, and M. Bitoun, 2015 Therapy for dominant inherited diseases by allele-specific RNA interference: successes and pitfalls. Curr. Gene Ther. 15: 503-510.
83. Truss, M., M. Swat, S. M. Kielbasa, R. Schafer, H. Herzel et al., 2005 HuSiDa-the human siRNA database: an open-access database for published functional siRNA sequences and technical details of efficient transfer into recipient cells. Nucleic Acids Res. 33: D108-D111.
84. Tyagi, A., F. Ahmed, N. Thakur, A. Sharma, G. P. Raghava et al., 2011 HIVsirDB: a database of HIV inhibiting siRNAs. PLoS One 6: e25917.
85. Ui-Tei, K., Y. Naito, F. Takahashi, T. Haraguchi, H. Ohki-Hamazaki et al., 2004 Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res. 32: 936-948.
86. Venter, J. C., M. D. Adams, E. W. Myers, P. W. Li, R. J. Mural et al., 2001 The sequence of the human genome. Science 291: 1304-1351.
87. Vert, J. P., N. Foveau, C. Lajaunie, and Y. Vandenbrouck, 2006 An accurate and interpretable model for siRNA efficacy prediction. BMC Bioinformatics 7: 520.
88. Watts, J. K., and D. R. Corey, 2012 Silencing disease genes in the laboratory and the clinic. J. Pathol. 226: 365-379.
89. Yu, D., H. Pendergraff, J. Liu, H. B. Kordasiewicz, D. W. Cleveland et al., 2012 Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150: 895-908.